Portal de investigação
EARLY HISTO-ENDOSCOPIC RESPONSE AT WEEK 12 PREDICTS CLINICAL OUTCOMES AT WEEK 52 WITH MIRIKIZUMAB IN ULCERATIVE COLITIS LUCENT TRIALS
Unidades de investigação
Abstract
Abstract no disponible
Filiações
Filiações não disponíveis
Proyectos asociados
Gut microbiome and IBD therapy: an interplay?
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (GutIBD) . 2021
Iron deficiency and inflammatory bowel disease. Correlation with inflammation and Vitamin D status.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (IronIBD) . 2021
Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (4WARD) . 2021
Isolated Ulceration of Crohn’s Anastomosis
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2022
Therapeutic Drug Monitoring: An Emergent Approach in Inflammatory Bowel Disease
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2019
Citar a publicação
Magro,F,Pai,R,Kobayashi,T,Jairath,V,Rieder,F,Redondo,I,Morris,N et al. EARLY HISTO-ENDOSCOPIC RESPONSE AT WEEK 12 PREDICTS CLINICAL OUTCOMES AT WEEK 52 WITH MIRIKIZUMAB IN ULCERATIVE COLITIS LUCENT TRIALS. Digestive Disease Week (DDW). 2023. 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA:W.B. Saunders Ltd. 2023 p.p. 885-885.
